HemoSense to Supply LabCorp(R) with INRatio System

  
    
  
  
    
      HemoSense, Inc. (AMEX:HEM) today announced that it has signed an 
      agreement with Laboratory Corporation of America® 
      Holdings (LabCorp®) 
      (NYSE:LH) to supply the HemoSense portable INRatio® 
      PT/INR monitoring system to identified LabCorp laboratories. The INRatio 
      system will also be made available to selected LabCorp patient service 
      centers and affiliated physician offices nationwide.
    
    
      HemoSense’s INRatio system consists of a 
      small, portable meter and disposable test strips that provide a quick 
      and accurate measurement of blood-clotting time, known as a PT/INR 
      value. This test helps patients reduce the risk of strokes through 
      frequent monitoring of anticoagulation therapy.
    
    
      “We are delighted to be working with a 
      recognized laboratory leader, and this agreement with LabCorp is one 
      more step toward our goal of increasing the HemoSense share of a growing 
      market in patient blood coagulation monitoring,” 
      said Timothy Still, executive VP and chief commercial officer of 
      HemoSense. “Monitoring patients’ 
      PT/INR levels at the point-of-care can help improve the treatment, 
      health and lifestyle of patients taking warfarin.”
    
    
      According to the U.S. Centers for Medicare & Medicaid Services (CMS), 
      monthly blood coagulation testing is inadequate for the majority of 
      patients on chronic warfarin therapy. HemoSense’s 
      INRatio system reduces the time and inconvenience required to manage 
      warfarin and allows patients to play an active role in management of 
      their warfarin dosage, encouraging optimal patient compliance, more time 
      spent within the patient’s therapeutic range 
      and immediate dose management. The INRatio system is based on a reliable 
      proprietary electrochemical technology that generates rapid PT/INR 
      results simultaneously with two levels of quality control from a single 
      drop of blood. Patient training is straightforward and test strips can 
      be stored at room temperature for up to one year.
    
    
      Tests performed using the INRatio system in the point-of-care setting 
      are currently reimbursed by Medicare and private payers for all patients 
      on warfarin. The INRatio system is sold through a prestigious and 
      growing network of distributors in the U.S. and internationally in 23 
      countries.
    
    
      About HemoSense
    
    
      HemoSense is a point-of-care diagnostic healthcare company that 
      develops, manufactures and markets easy-to-use, handheld blood 
      coagulation systems for monitoring patients taking warfarin. The 
      HemoSense INRatio system, used by healthcare professionals and patients 
      themselves, consists of a small monitor and disposable test strips. It 
      provides accurate and convenient measurement of blood clotting time, or 
      PT/INR values. Routine measurements of PT/INR are necessary for the safe 
      and effective management of the patient's warfarin dosing. INRatio is 
      sold in the United States and internationally. For more information, 
      visit www.hemosense.com.
    
    
      About LabCorp®
    
    
      Laboratory Corporation of America® 
      Holdings (LabCorp®), 
      a S&P 500 company, is a pioneer in commercializing new diagnostic 
      technologies and the first in its industry to embrace genomic testing. 
      With annual revenues of $3.6 billion in 2006, over 25,000 employees 
      nationwide, and more than 220,000 clients, LabCorp offers clinical 
      assays ranging from routine blood analyses to HIV and genomic testing. 
      LabCorp combines its expertise in innovative clinical testing technology 
      with its Centers of Excellence: The Center for Molecular Biology and 
      Pathology, in Research Triangle Park, NC; National Genetics Institute, 
      Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in 
      Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; 
      DIANON Systems, Inc. based in Stratford, CT; US LABS based in Irvine, 
      CA; and Esoterix and its Colorado Coagulation, Endocrine Sciences, and 
      Cytometry Associates laboratories. LabCorp clients include physicians, 
      government agencies, managed care organizations, hospitals, clinical 
      labs, and pharmaceutical companies. To learn more about LabCorp, visit www.LabCorp.com.
    
    
      HemoSense® and INRatio® 
      are registered trademarks of HemoSense, Inc.